Showing results (31-40 of 51) with videos related to
Sort By:
Pageof 6
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 9, 2008
Microscopic tumor burden in sentinel lymph nodes predicts synchronous nonsentinel lymph node involvement in patients with melanomaJeffrey E Gershenwald, Robert H I Andtbacka, Victor G Prieto, et al.Cancer|February 29, 2008
Lymphadenectomy for isolated lymph node metastasis from extremity soft-tissue sarcomasWaddah B Al-Refaie, Robert H I Andtbacka, Joe Ensor, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 31, 2021
Clinical Responses of Oncolytic Coxsackievirus A21 (V937) in Patients With Unresectable MelanomaRobert H I Andtbacka, Brendan Curti, Gregory A Daniels, et al.Journal of the American Academy of Dermatology|March 3, 2018
Similar survival of patients with multiple versus single primary melanomas based on Utah Surveillance, Epidemiology, and End Results data (1973-2011)Douglas Grossman, James M Farnham, John Hyngstrom, et al.American Journal of Physiology. Heart and Circulatory Physiology|June 8, 2014
Cardiac, skeletal, and smooth muscle mitochondrial respiration: are all mitochondria created equal?Song-Young Park, Jayson R Gifford, Robert H I Andtbacka, et al.Annals of Surgical Oncology|October 12, 2012
Sentinel lymph node biopsy for melanoma in pregnant womenRobert H I Andtbacka, Matthew R Donaldson, Tawnya L Bowles, et al.Cancer Research|April 6, 2006
Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cellsSteffan T Nawrocki, Jennifer S Carew, Maria S Pino, et al.Journal of the American Academy of Dermatology|December 31, 2013
Patterns of failure and predictors of outcome in cutaneous malignant melanoma of the scalpBreanne E Terakedis, Christopher J Anker, Sancy A Leachman, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 30, 2021
Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or LymphomasFunda Meric-Bernstam, Randy F Sweis, F Stephen Hodi, et al.Cancer Research Communications|March 16, 2023
Mavorixafor, an Orally Bioavailable CXCR4 Antagonist, Increases Immune Cell Infiltration and Inflammatory Status of Tumor Microenvironment in Patients with MelanomaRobert H I Andtbacka, Yan Wang, Robert H Pierce, et al.Pageof 6